阿奇霉素治疗住院COVID-19患者(RECOVERY):一项随机、对照、开放标签、平台试验
RECOVERY平台试验在英国176家医院纳入7763例住院COVID-19患者,随机分配至阿奇霉素500 mg每日一次(口服或静脉)用10天或至出院组(2582例)或仅常规治疗组(5181例)。结论:阿奇霉素不应常规用于住院COVID-19患者,仅限有明确抗菌指征时使用。
要点
- 住院COVID-19患者中阿奇霉素使用应限制于有明确抗菌指征者,不应作为常规抗炎或免疫调节治疗。
适用人群与场景
- 排除标准及具体纳入标准原文未详细提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 阿奇霉素500 mg每日一次,口服或静脉给药,疗程10天或至出院(或分配至其他RECOVERY治疗组)。
- 对照组仅接受常规标准治疗。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机、对照、开放标签、适应性平台试验(RECOVERY),英国176家医院参与。
- 样本量:7763例纳入阿奇霉素评估,阿奇霉素组2582例,常规治疗组5181例。
- 干预与对照:阿奇霉素500 mg每日一次(口服或静脉)用10天或至出院 vs 仅常规治疗。
- 不良事件原文未提及具体数据。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),开放标签,适应性平台设计。
- 证据等级或推荐强度:原文未提及。
- 局限:开放标签设计(参与者和当地研究人员未设盲),但其他试验人员对结局数据设盲;原文未提及其他局限。
对床旁实践的改变
- 住院COVID-19患者不应常规使用阿奇霉素作为免疫调节或抗炎治疗,因不改善生存及其他预设临床结局。
- 阿奇霉素使用应限制于有明确抗菌指征的住院COVID-19患者。
- 适用人群:住院COVID-19患者;不适用人群:无明确抗菌指征的住院COVID-19患者。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ISRCTN 50189673和ClinicalTrials.gov NCT04381936。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.
METHODS: In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
FINDINGS: Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87-1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98-1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87-1·03; p=0·24).
INTERPRETATION: In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication.
FUNDING: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
参考来源
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021. PMID: 33545096. doi:10.1016/S0140-6736(21)00149-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。